STTK: Shattuck Therapeutics Price to Sales
Shattuck Labs, Inc. (STTK) is developing a dual-function protein platform to combat cancer, paving the way for strategic partnerships. The GURU.Markets terminal displays the price-to-sales trend, where 456.70 represents the current metric. High patent barriers and FDA oversight limit competitor entry, while strict temperature controls during the transport of biologics ensure their complete integrity.
Shattuck Labs, Inc. (STTK) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Shattuck Labs, Inc.|STTK - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio shattucklabs.com|STTK - Company Total Debt|Debt to Book Capital Shattuck Therapeutics|STTK - Company Long-Term Liabilities|Company Short-Term Debts Shattuck Labs|Quick Liquidity Indicator shattucklabs.com
- net income and valuation ratios data:
STTK - Company Net Income|Projected Future Earnings Shattuck Labs, Inc.|STTK - Price to Earnings Ratio|Future Price to Earnings Multiple shattucklabs.com|STTK - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Therapeutics|STTK - Operating profit EBITDA|Net earnings per share (EPS TTM) Shattuck Labs|STTK - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months shattucklabs.com|STTK - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Shattuck Labs, Inc.
- issuer revenue and sales details:
Summary company analytics:Shattuck Labs Inc
The P/S ratio determines the market value of a business relative to its revenue, allowing for an assessment of the premium paid per unit of sales. Analyzing the price-to-sales metric helps identify imbalances between stock quotes and actual financial flows. The metric is calculated by dividing market capitalization by annual turnover, measuring the market's investment expectations. For Shattuck Labs, Inc. (STTK), this indicator reflects the speculative value of the GADLEN platform prior to the confirmation of immunotherapy efficacy in clinical trials.
Who Shattuck Labs, Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Market Cap to Revenue CLDX (Celldex)|Market Cap to Sales Volume AUPH|BioCryst - Market Cap to Revenue|Market Cap to Sales Volume VERA (veratx.com)|DNTH: Market Cap to Revenue|PHVS - P/S Multiple|ABCL: P/S Multiple|Market Cap to Revenue Tourmaline|Price-to-Revenue Ratio Precigen, Inc.|P/S Multiple pharming.com|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio - Price-to-Revenue Ratio|Gossamer Bio, Inc. - P/S Multiple|KALV - P/S Multiple|SEPN: P/S Multiple|PVLA (Pieris Pharma) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Savara Corp|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|ATXS (astriatx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO - Price-to-Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|KYTX: P/S Multiple|Market Cap to Revenue tizianalifesciences.com|Market Cap to Revenue CABA|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Price-to-Revenue Coefficient Avalo Therapeutics Inc|Eledon Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume AGEN (agenusbio.com)|CLYM: Market Cap to Revenue|Zura Bio Ltd - Market Cap to Sales Volume|aTyr (ATYR) - Price-to-Revenue Ratio|Adagene Inc. (ADAG) - P/S Multiple|Price-to-Revenue Ratio ImageneBio|Equillium Bio - Price-to-Sales Ratio|P/S Multiple CNTB|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|XFOR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Market Cap to Revenue SABS (SAB Biotherapeutics)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Market Cap to Revenue XTLB|P/S Multiple Bolt Bio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|HIND: P/S Multiple|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|Market Cap to Revenue CALI (CalciMedica, Inc.)|Market Cap to Sales Volume AFMD|Allakos - Market Cap to Revenue|Market Cap to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS: Market Cap to Revenue|ITOS - P/S Multiple|OCEA: P/S Multiple|Market Cap to Revenue TC BioPharm (Holdings) Plc|Price-to-Revenue Ratio Third Harmonic Bio, Inc
